세포 면역요법 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Cellular Immunotherapy Market size is expected to reach USD 93.52 Billion in 2034 from USD 14.87 Billion (2025) growing at a CAGR of 22.67% during 2026-2034.

The global cellular immunotherapy market is witnessing significant growth due to the rising prevalence of cancer and increasing demand for targeted treatment approaches. Innovations in CAR-T cell therapy and advanced gene-editing technologies are transforming oncology care and improving patient survival rates. Growing investments in biotechnology research, expanding clinical trials, and supportive regulatory approvals are accelerating commercialization. Pharmaceutical companies are enhancing manufacturing capabilities to meet rising demand. In the coming years, expanding indications beyond oncology and advancements in allogeneic therapies are expected to drive sustained market expansion worldwide.

Rising incidences of hematological malignancies and solid tumors remain key drivers of market growth. Technological advancements in cell engineering and processing techniques are improving therapeutic efficacy and safety profiles. Governments and private organizations are increasing funding for research initiatives to accelerate innovation. Strategic collaborations between biotech firms and academic institutions are strengthening product pipelines. Improved reimbursement frameworks in developed countries are enhancing patient access. As awareness of personalized medicine grows, demand for customized immunotherapies will continue to expand steadily.

The increasing focus on precision medicine is reshaping global treatment paradigms. Automation in cell processing and manufacturing is helping reduce costs and improve scalability. Strong clinical evidence demonstrating durable remission benefits is building confidence among healthcare providers. Biopharmaceutical companies are investing in next-generation off-the-shelf therapies to broaden accessibility. Emerging markets are gradually improving healthcare infrastructure, creating new growth opportunities. With continuous research and technological refinement, the cellular immunotherapy market is poised for long-term sustainable development.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapy Type

• CAR T Cell Therapy
• Dendritic Cell Therapy
• NK Cell Therapy
• TIL Therapy
• Others

By Indication

• B-cell Malignancies
• Prostate Cancer
• Liver Cancer
• Renal Cell Carcinoma
• Others

By End Use

• Hospitals
• Cancer Institutes
• Others

COMPANIES PROFILED

• BristolMyers Squibb Company, , Novartis AG, Gilead Sciences Inc Kite Pharma, F HoffmannLa Roche Ltd, Merck KGaA, GlaxoSmithKline plc, AstraZeneca, Pfizer Inc, Johnson Johnson, Celyad, Adicet Bio Inc, Dendreon Pharmaceuticals LLC
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Type
• 4.2. CAR T Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Dendritic Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. NK Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. TIL Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. B-cell Malignancies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Renal Cell Carcinoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELLULAR IMMUNOTHERAPY MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cancer Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapy Type
  • 7.2.2 By Indication
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapy Type
  • 7.3.2 By Indication
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapy Type
  • 7.4.2 By Indication
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapy Type
  • 7.5.2 By Indication
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapy Type
  • 7.6.2 By Indication
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CELLULAR IMMUNOTHERAPY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Novartis AG
  • 9.2.2 Gilead Sciences Inc. (Kite Pharma)
  • 9.2.3 F. Hoffmann-La Roche Ltd
  • 9.2.4 Merck KGaA
  • 9.2.5 GlaxoSmithKline Plc
  • 9.2.6 AstraZeneca
  • 9.2.7 Pfizer Inc
  • 9.2.8 Johnson & Johnson
  • 9.2.9 Celyad
  • 9.2.10 Adicet Bio Inc
  • 9.2.11 Dendreon Pharmaceuticals LLC